Israeli biotech company UltraSight and South Korean biotech firm Mediana, a subsidiary of SelvasAI, have joined forces to develop an innovative cardiovascular diagnostic platform that incorporates artificial intelligence (AI) echocardiography.
The Yozma Group announced on Monday that Ultrasight, one of its investment companies, is collaborating with Mediana to create a cutting-edge cardiovascular diagnostic platform. This platform will integrate wearable electrocardiograms (ECG), patient monitoring devices (PMD), and AI echocardiography.
Ultrasight’s AI echocardiography solution is designed to empower medical professionals, even those without ultrasound experience, to capture diagnostic-quality heart images through real-time AI guidance.
The company has garnered strategic investments and partnerships from world-renowned institutions, including the Mayo Clinic and Weizmann Institute, allowing it to continuously refine the precision and clinical reliability of its AI algorithms.
Ultrasight is currently accelerating its global market entry by securing product approvals from regulatory agencies worldwide. Notably, Johnson & Johnson has made a strategic investment and is collaborating with Ultrasight on AI ultrasound technology.
Mediana specializes in real-time patient vital sign monitoring through PMD and wearable ECG technology. As of this month, over 4,000 hospital beds are equipped with Mediana’s solutions.
The company plans to develop an integrated solution that leverages Ultrasight’s AI echocardiography technology to support the entire process from detecting cardiovascular abnormalities to diagnosis.
Mediana’s strategy aims to broaden its business scope by incorporating AI diagnostic capabilities into its existing patient monitoring services. This expansion will create a comprehensive platform that covers disease prevention, early diagnosis, and monitoring, while also assisting healthcare providers in their decision-making process.
The global echocardiography market is projected to grow from approximately 3 trillion KRW (about 1.98 million USD) in 2024 to around 6 trillion KRW (about 3.97 million USD) by 2034.
The market for AI-based cardiovascular diagnostic solutions is expected to see continued growth, driven by the increasing demand for improved diagnostic efficiency in clinical settings.
Yoon Seung-hyun, Chief Executive Officer (CEO) of Mediana, stated that it’s developing a platform that supports the entire lifecycle of cardiovascular disease management by integrating wearable ECG, PMD, and AI echocardiography. The goal is to expand the medical platform business significantly.
The Yozma Group, acting as a global venture capital firm, identifies promising technology-based startups, including those in Israel, and facilitates connections with large and medium-sized enterprises. The group plays a crucial role in supporting joint commercialization efforts and international expansion for these innovative companies.
